ATP5MD

Across TCGA pan-cancer cohorts, ATP5MD RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ATP5MD’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ATP5MD RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ATP5MD is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.

LIHC, UCEC, and BRCA are the cancer types where ATP5MD tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP5MD RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.993	<.001	9	view →
UCEC	All	All	+0.722	<.001	8	view →
BRCA	Female	II,III,IV	+0.245	<.001	6	view →
COAD	All	All	−0.393	.001	5	view →
LUAD	All	All	+0.318	<.001	4	view →
CHOL	All	All	+0.782	<.001	3	view →
LUSC	All	All	+0.387	<.001	3	view →
STAD	Female	All	+0.542	.049	2	view →
KIRC	Female	IV	+0.616	<.001	1	view →
READ	All	All	−0.527	.026	1	view →
KICH	All	All	−0.285	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ATP5MD–LIHC

Open the LIHC breakdown →